<DOC>
	<DOCNO>NCT02758730</DOCNO>
	<brief_summary>This randomize , placebo-controlled , parallel group , patient-blind , single-center phase I clinical trial repeat every 4 week administration subcutaneous injection AFFITOPE® PD01A , adsorb aluminium oxide 30 patient PD-GBA treatment period 8 week . Patients randomize 2:1 ratio two different treatment group : A ) 75 µg AFFITOPE® PD01A , adsorb aluminium oxide B ) placebo ( = 1 mg aluminium oxide ) . Over study duration 52 week , patient receive 3 injection AFFITOPE® PD01A placebo participation clinical trial . Patients either receive 75 µg AFFITOPE® PD01A adsorb 1 mg aluminium oxide placebo ( =1mg aluminium oxide ) . The treatment group consist 20 PDGBA patient , placebo group 10 PDGBA patient . Male female patient age 40 80 year participate trial . AFF010 part project MULTISYN fund European Commission ( FP7-HEALTH-2013-INNOVATION-1 project ; N° HEALTH-F4-2013-602646 ) .</brief_summary>
	<brief_title>Study Assessing Tolerability Safety Exploring Immunogenicity Therapeutic Activity AFFITOPE® PD01A PD-GBA Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Confirmed diagnosis Parkinson 's disease confirm carrier status heterozygous GBA mutation ( PDGBA ) Individuals present Hoehn &amp; Yahr Stages I/II/III fulfill United Kingdom Parkinson 's Disease Society Brain Bank Criteria Confirmed carrier status heterozygous GBA mutation ( PDGBA ) The result MRI scan patient 's brain consistent diagnosis PD Written inform consent sign dated patient , preferentially , caregiver ( caregiver mandatory ) Age 40 80 In investigator 's opinion , visual auditory impairment would reduce patient ' ability complete study questionnaire unable receive instruction Female patient childbearing potential eligible use medically accept contraceptive method A potential participant treat conventional PD therapy must stable dos least 3 month prior Visit 1 entire trial period Accepted PD medication include follow : levodopa ( alone combination benserazide , carbidopa ) , catecholOmethyltransferase ( COMT ) inhibitor ( entacapone , tolcapone ) , amantadine , nonergot dopamine agonist ( pramipexol , ropinirol , rotigotine ) , monoamine oxidaseB ( MAOB ) inhibitor ( rasagiline , selegiline ) anticholinergic medication A potential participant stable dos medication he/she take consist illness accord medical history ( except PD therapy , record separately ) least 30 day prior Visit 1 consider relevant investigator Able communicate well investigator , understand comply requirement study Pregnant woman Sexually active woman childbearing potential use medically accept birth control method Participation another clinical trial within 3 month Visit 1 History questionable compliance visit schedule ; patient expect complete clinical trial Presence history allergy component vaccine consider relevant investigator Contraindication MRI image metallic implant ( e.g . endoprosthesis , stent , cardiac pacemaker ) MR compatible 3.0 Tesla give MR protocol , foreign metal body ( e.g . bullet , metal splinter , e.g . ) claustrophobia Missing agreement inform incident finding consultation neuroradiologist Contraindication PET , , pregnancy breast feeding . Ongoing participation interventional study clinical trial use radiotracers Dementia accord Diagnostic Statistical Manual ( DSM ) IV criterion History and/or presence autoimmune disease , consider relevant investigator Recent ( ≤3 year since last specific treatment ) history cancer ( Exceptions : nonmelanoma skin cancer , intraepithelial cervical neoplasia ) Active infectious disease ( e.g. , Hepatitis B , C ) Presence and/or history Immunodeficiency ( e.g. , HIV ) Significant systemic illness ( e.g. , chronic renal failure , chronic liver disease , poorly control diabetes , poorly control congestive heart failure , deficiency ) , consider relevant investigator History significant psychiatric illness schizophrenia , bipolar affective disorder psychotic depression Parkinsonlike disease secondary drug therapy side effect ( e.g. , due exposure medication deplete dopamine [ reserpine , tetrabenazine ] block dopamine receptor [ neuroleptic , antiemetic ] ) Parkinsonplus syndrome ( e.g. , multiple system atrophy ( MSA ) , progressive supranuclear palsy ( PSP ) ) , Dementia Lewy Bodies ( DLB ) Heredodegenerative disorder PDGBA , evidence genetic form PD ( e.g . LRRK2 , Parkin gene mutation ) Alcoholism substance abuse within past year ( alcohol drug intoxication ) Prior and/or current treatment experimental immunotherapeutics include Intravenous Immunoglobulin ( IVIG ) Prior and/or current treatment immune modulate drug : 1 . Interleukins , Interferons , Tumor Necrosis Factor ( TNF ) analogue , colony stimulate factor compound 2 . Ciclosporin , Tacrolimus , Sirolimus analogues 3 . Cytostatic drug certain DMARD rheumatoid arthritis ( similar autoimmune disorder ) ( e.g . Cyclophosphamid , Azathioprin , methotrexate , sulfasalazine , leflunomide , sodium aurothiomalate ( Gold ) , cyclosporin ) analogues 4 . Systemic ( gluco ) corticoid therapy 5 . All antibody therapy ( e.g. , anti cluster differentiation 3 ( CD3 ) , anti cluster differentiation 25 ( CD25 ) also antilymphocyte globulin ) might modulate , enhance weaken immune response Change dose standard treatment PD within 3 month prior Visit 1 Change dose previous current medication patient take consist illness accord medical history ( except PD therapy , record separately ) within last 30 day prior Visit 1 , clinically relevant Treatment deep brain stimulation Venous status render impossible place i.v . access</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>GBA mutation</keyword>
</DOC>